Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 13Unknown 4Terminated 3Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × TH 302 × Clear all
NCT01864538 2025-05-11

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

ImmunoGenesis

Phase 2 Terminated
11 enrolled 8 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT02047500 2025-05-11

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

ImmunoGenesis

Phase 1 Terminated
19 enrolled 6 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02255110 2018-12-14

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Merck KGaA, Darmstadt, Germany

Phase 2 Terminated
6 enrolled 6 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡